Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Amneal Pharmaceuticals Inc's Business Segments
Amneal Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
3
Largest Segment
Affordable Medicines
Total Revenue
$ 722
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Affordable Medicines58.6%
- AvKARE23%
- Amneal Specialty Pharma18.5%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Affordable Medicines | $ 423 | 58.6% |
| AvKARE | $ 166 | 23% |
| Amneal Specialty Pharma | $ 133 | 18.5% |
Revenue by Product & Service Category - Q1 FY2026
- Subtotal Dosage Forms57.9%
- Oral Solid23.7%
- Subtotal Therapeutic Classes18.5%
- Distribution Service12.3%
- Central Nervous System11.5%
- Transdermal10.2%
- Government Label8.3%
- Injectable6.9%
- Other Dosage Forms6.5%
- Ephinephrine Auto-Injector5.8%
- Hormonal Allergy5%
- Biosimilar3.1%
- Other Therapeutic Classes1.9%
- Oral Liquid1.7%
- Institutional1.4%
- Product and Service, Other1%
- International0.7%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Subtotal Dosage Forms | $ 418 | 57.9% |
| Oral Solid | $ 171 | 23.7% |
| Subtotal Therapeutic Classes | $ 133 | 18.5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
14 more categories available
Sign in to unlock the full Amneal Pharmaceuticals Inc dataset.
Description of Amneal Pharmaceuticals Inc
Amneal Pharmaceuticals Inc. is a global pharmaceutical company that specializes in the development, manufacture, and distribution of high-quality generic and branded pharmaceutical products. The company was founded in 2005 by Chirag and Chintu Patel, and is headquartered in Bridgewater, New Jersey, United States.
Amneal has a broad portfolio of products that spans across various therapeutic areas, including CNS disorders, gastrointestinal disorders, cardiovascular diseases, and pain management. The company's products are distributed in more than 150 countries worldwide, through a combination of direct sales, strategic partnerships, and licensing agreements.
Amneal Pharmaceuticals has several manufacturing facilities that operate under strict quality control guidelines and adhere to international regulatory standards. The company's manufacturing facilities are located in the United States, India, Germany, the United Kingdom, and Ireland.
The company has a strong research and development (R&D) pipeline that focuses on developing novel pharmaceutical products using innovative delivery technologies. The R&D team consists of experienced scientists and researchers who work in state-of-the-art laboratories and collaborate with academic institutions and other pharmaceutical companies to develop new and innovative products.
Amneal Pharmaceuticals has received numerous awards and recognitions for its contribution to the pharmaceutical industry. In 2020, the company was named "Generics Company of the Year" by the Generic Pharmaceutical Association (GPhA) and ranked #331 in the Fortune 500 list.
The company's mission is to improve patient health by providing high-quality, affordable pharmaceutical products to people around the world. The company is committed to sustainability and ethical business practices, and has a strong corporate social responsibility program that supports community development, education, and environmental conservation initiatives.
In summary, Amneal Pharmaceuticals Inc. is a global pharmaceutical company that specializes in the development, manufacture, and distribution of high-quality generic and branded pharmaceutical products. The company has a broad portfolio of products that are distributed in more than 150 countries worldwide, and has a strong research and development pipeline that focuses on developing innovative pharmaceutical products. The company is committed to sustainability and ethical business practices, and has a strong corporate social responsibility program.
Amneal has a broad portfolio of products that spans across various therapeutic areas, including CNS disorders, gastrointestinal disorders, cardiovascular diseases, and pain management. The company's products are distributed in more than 150 countries worldwide, through a combination of direct sales, strategic partnerships, and licensing agreements.
Amneal Pharmaceuticals has several manufacturing facilities that operate under strict quality control guidelines and adhere to international regulatory standards. The company's manufacturing facilities are located in the United States, India, Germany, the United Kingdom, and Ireland.
The company has a strong research and development (R&D) pipeline that focuses on developing novel pharmaceutical products using innovative delivery technologies. The R&D team consists of experienced scientists and researchers who work in state-of-the-art laboratories and collaborate with academic institutions and other pharmaceutical companies to develop new and innovative products.
Amneal Pharmaceuticals has received numerous awards and recognitions for its contribution to the pharmaceutical industry. In 2020, the company was named "Generics Company of the Year" by the Generic Pharmaceutical Association (GPhA) and ranked #331 in the Fortune 500 list.
The company's mission is to improve patient health by providing high-quality, affordable pharmaceutical products to people around the world. The company is committed to sustainability and ethical business practices, and has a strong corporate social responsibility program that supports community development, education, and environmental conservation initiatives.
In summary, Amneal Pharmaceuticals Inc. is a global pharmaceutical company that specializes in the development, manufacture, and distribution of high-quality generic and branded pharmaceutical products. The company has a broad portfolio of products that are distributed in more than 150 countries worldwide, and has a strong research and development pipeline that focuses on developing innovative pharmaceutical products. The company is committed to sustainability and ethical business practices, and has a strong corporate social responsibility program.
Amneal Pharmaceuticals Inc. is a fully integrated pharmaceutical company that specializes in the development, manufacturing, and distribution of a diverse range of high-quality generic and branded pharmaceutical products. The companys operations are categorized into two distinct segments: Generics and Specialty.
Segments
1. Generics:
This segment is largely focused on creating affordable alternatives to brand-name medications. Amneals extensive portfolio includes products in various dosage forms such as:
- Tablets and Capsules: These are common forms of medication, addressing multiple therapeutic areas including cardiovascular, CNS, and dermatology.
- Injectables: These products cater to a variety of medical needs, including critical care and chronic conditions.
- Ophthalmics: Medications targeting eye health issues.
- Liquids: Liquid formulations for patients who may have difficulty swallowing solid dosage forms.
- Transdermal Patches: Innovative delivery systems that provide steady absorption of medication through the skin over time.
Therapeutic Areas:
Amneals generics cover a wide spectrum of therapeutic areas, including:
- Oncology: Generic solutions for cancers encompassing breast, lung, prostate, and others.
- CNS (Central Nervous System): Medications for mood disorders such as depression and anxiety, as well as treatments for migraines.
- Cardiovascular: Includes drugs aimed at managing hypertension, cholesterol levels, and offering antiplatelet therapies.
- Dermatology: Generic options for skin-related issues such as acne, psoriasis, and atopic dermatitis.
- Women’s Health: Offering options for contraception and hormone replacement therapy.
- Ophthalmics: Products addressing various ocular conditions.
2. Specialty:
The Specialty segment emphasizes the development and commercialization of branded prescription pharmaceuticals with a concentration in specific high-need therapeutic categories. This segment features:
- Neuroscience: Products tailor-made for conditions such as migraines and bipolar disorder, highlighting the company’s commitment to addressing complex central nervous system disorders.
- Women’s Health: Branded products for contraception, menopause-related therapies, and womens reproductive health.
- Oncology: This includes specialized treatments for conditions like multiple myeloma and metastatic breast cancer, which require focused therapeutic approaches.
Products
Amneal Pharmaceuticals delivers a comprehensive line of pharmaceutical products stemming from both segments, ensuring effective treatment options across various therapeutic areas.
- Generics:
- Cardiovascular medications (hypertension, cholesterol, antiplatelet drugs)
- CNS treatments (antidepressants, anxiolytics, migraine medications)
- Dermatological solutions (acne treatments, psoriasis medication)
- Oncology drugs (therapeutics for a range of cancers)
- Women’s health products (contraceptives, hormone therapies)
- Ophthalmic treatments (eye care solutions)
- Specialty:
- Neuroscience products (migraine treatments, therapies for bipolar disorders)
- Women’s health offerings (hormonal therapies, contraceptives)
- Specialty oncology products (aimed at treating complex forms of cancer)
Services
Beyond its pharmaceutical products, Amneal Pharmaceuticals also provides a suite of related services that support the broader pharmaceutical landscape:
- Contract Manufacturing: The company offers manufacturing services to other pharmaceutical firms, leveraging its manufacturing capabilities and technology to produce medications under contract.
- Research and Development (R&D): Amneal invests in R&D to innovate and enhance existing pharmaceutical products, as well as to explore the development of new drugs to meet evolving healthcare needs.
- Licensing and Partnerships: Amneal engages in strategic licensing and partnership agreements that allow the company to expand its product portfolio and enhance its reach into various geographic markets.
- Distribution Services: The company plays a crucial role in the pharmaceutical supply chain by distributing its products to wholesalers, retailers, and healthcare providers, thereby ensuring availability for patients.
Overall, Amneal Pharmaceuticals Inc. stands out as a fully integrated pharmaceutical entity, offering a rich variety of generic and branded products, alongside pertinent services necessary for the effective functioning of the pharmaceutical industry. The emphasis on quality and a broad therapeutic focus positions the company as a key player in the healthcare market.
Segments
1. Generics:
This segment is largely focused on creating affordable alternatives to brand-name medications. Amneals extensive portfolio includes products in various dosage forms such as:
- Tablets and Capsules: These are common forms of medication, addressing multiple therapeutic areas including cardiovascular, CNS, and dermatology.
- Injectables: These products cater to a variety of medical needs, including critical care and chronic conditions.
- Ophthalmics: Medications targeting eye health issues.
- Liquids: Liquid formulations for patients who may have difficulty swallowing solid dosage forms.
- Transdermal Patches: Innovative delivery systems that provide steady absorption of medication through the skin over time.
Therapeutic Areas:
Amneals generics cover a wide spectrum of therapeutic areas, including:
- Oncology: Generic solutions for cancers encompassing breast, lung, prostate, and others.
- CNS (Central Nervous System): Medications for mood disorders such as depression and anxiety, as well as treatments for migraines.
- Cardiovascular: Includes drugs aimed at managing hypertension, cholesterol levels, and offering antiplatelet therapies.
- Dermatology: Generic options for skin-related issues such as acne, psoriasis, and atopic dermatitis.
- Women’s Health: Offering options for contraception and hormone replacement therapy.
- Ophthalmics: Products addressing various ocular conditions.
2. Specialty:
The Specialty segment emphasizes the development and commercialization of branded prescription pharmaceuticals with a concentration in specific high-need therapeutic categories. This segment features:
- Neuroscience: Products tailor-made for conditions such as migraines and bipolar disorder, highlighting the company’s commitment to addressing complex central nervous system disorders.
- Women’s Health: Branded products for contraception, menopause-related therapies, and womens reproductive health.
- Oncology: This includes specialized treatments for conditions like multiple myeloma and metastatic breast cancer, which require focused therapeutic approaches.
Products
Amneal Pharmaceuticals delivers a comprehensive line of pharmaceutical products stemming from both segments, ensuring effective treatment options across various therapeutic areas.
- Generics:
- Cardiovascular medications (hypertension, cholesterol, antiplatelet drugs)
- CNS treatments (antidepressants, anxiolytics, migraine medications)
- Dermatological solutions (acne treatments, psoriasis medication)
- Oncology drugs (therapeutics for a range of cancers)
- Women’s health products (contraceptives, hormone therapies)
- Ophthalmic treatments (eye care solutions)
- Specialty:
- Neuroscience products (migraine treatments, therapies for bipolar disorders)
- Women’s health offerings (hormonal therapies, contraceptives)
- Specialty oncology products (aimed at treating complex forms of cancer)
Services
Beyond its pharmaceutical products, Amneal Pharmaceuticals also provides a suite of related services that support the broader pharmaceutical landscape:
- Contract Manufacturing: The company offers manufacturing services to other pharmaceutical firms, leveraging its manufacturing capabilities and technology to produce medications under contract.
- Research and Development (R&D): Amneal invests in R&D to innovate and enhance existing pharmaceutical products, as well as to explore the development of new drugs to meet evolving healthcare needs.
- Licensing and Partnerships: Amneal engages in strategic licensing and partnership agreements that allow the company to expand its product portfolio and enhance its reach into various geographic markets.
- Distribution Services: The company plays a crucial role in the pharmaceutical supply chain by distributing its products to wholesalers, retailers, and healthcare providers, thereby ensuring availability for patients.
Overall, Amneal Pharmaceuticals Inc. stands out as a fully integrated pharmaceutical entity, offering a rich variety of generic and branded products, alongside pertinent services necessary for the effective functioning of the pharmaceutical industry. The emphasis on quality and a broad therapeutic focus positions the company as a key player in the healthcare market.